News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 672 results
May 2018
-
Media ReleaseNovartis data at ASCO and EHA reinforce company's commitment to reimagining cancer- Results from the Kisqali® MONALEESA clinical trial program, the largest industry-sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be…
-
Media ReleaseAlcon teams up with Venus Williams, tennis champion and dry eye sufferer, to launch Systane® Complete eye dropsThe new product joins the #1 doctor recommended Systane family of dry eye drops as the brand's most advanced solution to dateAlcon launches multimedia campaign to reach the 30 million people living…
-
Media ReleaseNovartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
-
Media ReleaseAlcon teams up with Venus Williams, tennis champion and dry eye sufferer, to launch Systane® Complete eye drops
-
Media ReleaseNovartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis- New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)(1)- In a landmark…
-
Media ReleaseNovartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
-
Media ReleaseKymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphomaKymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response1Kymriah is the only CAR-T…
-
Media ReleaseKymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
-
Media ReleaseAlcon Introduces AIR OPTIX® COLORS Contact Lenses Gemstone Collection, Creating New Ways to Enhance and Play with Eye Color
April 2018
-
Media ReleaseNew Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval- Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week 48…
-
Media ReleaseNew Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
-
Media ReleaseNovartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home- FocalView is a first-of-its-kind app designed to modernize ophthalmic clinical trials, making them more accessible and flexible- Using patients' self-recorded measurements, FocalView aims to enable…
Pagination
- ‹ Previous page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- …
- 56
- › Next page